Celgene CEO: We don’t have to be No. 1 to thrive with new cancer therapy to replace chemo – CNBC
CNBC |
Celgene CEO: We don't have to be No. 1 to thrive with new cancer therapy to replace chemo
CNBC [are] realizing is that this class of medicine of CAR T therapy — whether its lymphoma, leukaemia or myeloma — will replace existing chemotherapy," Alles said in a "Squawk Box" interview. CAR T-cell therapy takes a patient's own immune cells, called … |
